Jordyn Sava is an editor for Targeted Oncology.
European Commission Approves Mosunetuzumab for Patients with R/R Follicular Lymphoma
June 12th 2022The European Commission has granted a conditional marketing authorization to mosunetuzumab for the treatment of adult patients with relapsed or refractory follicular lymphoma who have previously received at least 2 prior systemic therapies
Anti-CD19 CAR T Cells for the Treatment of Relapsed/Refractory NHL
June 1st 2022In an interview with Targeted Oncology, Manali Kamdar, MD, discussed the current relapsed/refractory B-cell non-Hodgkin lymphoma space, along with data from the phase 1 clinical trial of an anti-CD19 CAR T-cell product for these patients.
Sugemalimab Demonstrates Clinically Meaningful PFS Boost in Unresectable NSCLC
May 26th 2022GEMSTONE-301 showed sugemalimab to demonstrate a statistically significant and clinically meaningful improvement in progression-free survival in patients with unresectable stage 3 non-small cell lung cancer without disease progression after concurrent or sequential chemoradiotherapy.
BLA Submitted to the FDA for N-803 Plus BCG in BCG-Unresponsive Bladder Cancer
May 25th 2022A biologics license application has been submitted to the FDA for N-803 plus Bacillus Calmette-Guérin as treatment for patients with BCG-unresponsive non-muscle invasive bladder cancer in situ with or without Ta or T1 disease.
High-Dose Anakinra Shows Promise in Treating CRS/ICANS Post CAR T-Cell Therapy
May 18th 2022In an interview with Targeted Oncology, Nicolas Gazeau, further discusses his analysis of anakinra when administered at 2 different dose regimens for patients with refractory CRS/ICANS after CAR T-cell therapy.